SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of various crypto tokens attempting to capitalize on the highly anticipated, multi-trillion dollar SpaceX IPO. While some participants are seeking exposure through the tokenized assets, others are warning of a potential scam, urging caution against the speculative hype surrounding Elon Musk's companies.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is experiencing significant volatility and downward pressure as investors navigate sector-wide weakness and frustration over the stock's inability to maintain gains despite steady contract wins. While the community is actively debating whether the stock has bottomed or needs more time to heal, many remain bullish on the long-term outlook, highlighting strong fundamental backlog and the company's role in government, nuclear, and space infrastructure as key reasons to maintain their positions.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors scrutinize the company's $125 million acquisition by Garda Therapeutics at $18 per share, which many long-term shareholders feel significantly undervalues the core Rolvedon asset and follows a series of questionable portfolio divestitures. The community remains highly vocal about potential fiduciary failures, expressing intense frustration over management's decision-making and demanding accountability while waiting for the Schedule 14D-9 to clarify the valuation process.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining significant traction among investors who are actively discussing its potential to benefit from domestic supply chain reshoring and a strategic focus on metals-tech integration. The community sentiment is polarized between those viewing it as a resilient, long-term play in a volatile metals market and skeptics who are cautious about low-volume trading patterns, bot activity, and the inherent risks associated with its recent deSPAC transition.

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

4D Molecular Therapeutics is attracting significant attention as investors react to positive Phase 2 SPECTRA trial data for 4D-150 in diabetic macular edema, sparking discussions about its potential as a best-in-class, durable gene therapy. While the community is actively debating the company's valuation relative to its cash position and the timeline for upcoming pivotal data, momentum traders are closely monitoring price action and short interest as the company prepares for upcoming investor conferences.

Invesco Exchange-Traded Fund Trust II - Invesco S&P 500 Momentum ETF

Invesco S&P 500 Momentum ETF

The Invesco S&P 500 Momentum ETF (SPMO) is trending as investors debate its ability to outperform traditional benchmarks, particularly following its semi-annual rebalancing. The community is actively discussing whether to use this fund as a core long-term holding for its historical growth performance or to pivot toward more flexible, actively managed alternatives.

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI Pharmaceuticals Inc

ANI Pharmaceuticals is experiencing positive momentum driven by strong demand for its rare disease franchise, particularly Cortrophin Gel, and a robust pipeline of new product launches. The community is actively discussing the company's improved financial guidance and strategic efforts to scale its rare disease portfolio, while some remain cautious about broader sector headwinds and historical share price performance.

Modine Manufacturing Co. engages in the provision of thermal management products and solutions. It operates through the Climate Solutions and Performance Technologies business segments. The Climate Solutions segment provides climate-controlled solutions and components, heat transfer products, heating, ventilating, air conditioning and refrigeration products, and data center cooling solutions. The Performance Technologies segment designs and manufactures air- and liquid-cooled technology for vehicular, stationary power, and industrial applications. In addition, the Performance Technologies segment provides thermal solutions to zero-emission and hybrid commercial vehicle and automotive customers, and coating products and application services. The company was founded by Arthur B. Modine on June 23, 1916 and is headquartered in Racine, WI.

Modine Manufacturing Co.

Modine Manufacturing is capturing intense investor attention as it positions itself as a pure-play leader in data center thermal management, a critical infrastructure bottleneck for the surging AI and hyperscale compute sector. The community is actively debating the company's valuation against its aggressive growth targets and upcoming spinoff, with many tracking it alongside industry peers as a key play on physical AI infrastructure.

Vishay Intertechnology, Inc. engages in the manufacture and distribution of discrete semiconductors and passive electronic components. It operates through the following segments: MOSFET (metal oxide semiconductor field-effect transistor), Diodes, Optoelectronic Components, Resistors, Inductors, and Capacitors. The MOSFET segment offers semiconductors which function as solid state switches to control power. The Diodes segment produces semiconductors which route, regulate, and block radio frequency, analog, and power signals, protect systems from surges or electrostatic discharge damage, and provide electromagnetic interference filtering. The Optoelectronic Components segment includes components that emit light, detect light, or do both. The Resistors and Inductors segment deals with components that impede electric current. The Capacitors segment provides components which store energy and discharge it when needed. The company was founded by Felix Zandman in 1962 and is headquartered in Malvern, PA.

Vishay Intertechnology, Inc.

Vishay Intertechnology is attracting significant investor interest as a foundational semiconductor recovery play, driven by robust call option activity and its strategic positioning in high-growth infrastructure sectors like smart home sensing and grid modernization. The community is actively discussing its potential for structural growth as the company transitions from low-volatility accumulation into a more active trend phase, buoyed by expanding volume and key component demand.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is generating significant interest as investors weigh its tech-heavy exposure and monthly dividend yield against market volatility, with the community actively debating whether to hold the fund for consistent income or rotate into higher-yielding alternatives. Traders are closely monitoring a psychological price barrier near $60, viewing the recent market fluctuations as a potential entry point for long-term positions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients.read more...

Equities Analysts Offer Predictions for TARA FY2028 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities research analysts at HC Wainwright raised their FY2028 EPS estimates for shares of Protara Therapeutics in a research note issued to investors on Wednesday, April 29th. HC Wainwright analyst A. Maldonado now expects that the company w...

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, f...

Stock Traders Buy Large Volume of Protara Therapeutics Call Options (NASDAQ:TARA)

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders bought 2,120 call options on the stock. This represents an...

Jacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 22,598 shares of Protara Therapeutics stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the sale...

Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 22,598 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total transaction of $118,865.48. Following the transaction, the...

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports...

Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling...

Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February

Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 4,895,488 shares, an...

FY2030 Earnings Forecast for TARA Issued By HC Wainwright

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Protara Therapeutics in a research note issued...

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

TARA
Protara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest TARA News

TARAProtara Therapeutics Inc